Meta AnalysisID 1356
抗凝血酶预防极早产儿脑室内出血 [Cochrane协议]
CRD42015026195
To assess whether the prophylactic administration of antithrombin (started within the first 24 hours after birth) compared to placebo, no treatment, or heparin, reduces the incidence of germinal matrix-intraventricular h
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Meta-analysis: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final meta_analysis record.
- Meta Analysis Id
- 1356
- Evidence Id
- 9914
- Core Evidence Id
- 9914
- Source Meta Analysis Id
- 1315
- Herb2 Meta Analysis Id
- HBMA001315
- Crd Id
- CRD42015026195
- Title
- Antithrombin for the prevention of intraventricular hemorrhage in very preterm infants [Cochrane Protocol]
- Review Question
- To assess whether the prophylactic administration of antithrombin (started within the first 24 hours after birth) compared to placebo, no treatment, or heparin, reduces the incidence of germinal matrix-intraventricular hemorrhage in preterm neonates at risk of intraventricular hemorrhage. Subgroup analysis will address gestational age, birth weight, requirement for assisted ventilation, plasma-derived versus recombinant antithrombin (see Subgroup analysis and investigation of heterogeneity).
- Study Type Included
- We will include prospective randomized controlled clinical trials, quasi-randomized trials and cluster trials. We will exclude cross-over trials. Studies where antithrombin is administered to ensure appropriate anticoagulation (e.g., during extracorporeal membrane oxygenation) are beyond the scope of the present review.
- Condition Being Studied
- The Cochrane Neonatal Group
- Participant
- Infant newborns admitted to neonatal intensive care units, gestational age < 32 weeks, any birth weight. We will exclude trials where antithrombin, regardless of the dosage, is administered during extracorporeal membrane oxygenation.
- Animal
- Human Disease Modelled
- Intervention
- <ol> Antithrombin compared to placebo or no treatment (specific subgroup analyses for each comparison are described in Subgroup analysis and investigation of heterogeneity) Antithrombin compared to unfractionated heparin Antithrombin compared to low-molecular-weight heparin</ol> We will include any dose, mode of administration, and duration of antithrombin therapy in this review. As the aim of the review is to assess the ability of antithrombin to prevent germinal matrix-intraventricular hemorrhage, we will only include studies in which antithrombin administration was started within the first 24 hours of life.
- Comparator Control
- <ol> Antithrombin compared to placebo or no treatment (specific subgroup analyses for each comparison are described in Subgroup analysis and investigation of heterogeneity) Antithrombin compared to unfractionated heparin Antithrombin compared to low-molecular-weight heparin </ol>
- Main Outcome
- Intraventricular hemorrhage: Any severity, grade 1 to 4 according to Papile 1978 Severe intraventricular hemorrhage: grade 3 and 4 according to Papile 1978 </ul>
- Outcome Measure
- Additional Outcome
- Mortality: neonatal mortality (< 28 days of age); infant mortality (one year of age) Bronchopulmonary dysplasia/chronic lung disease 28 days (NIH 1979) 36 weeks postmenstrual age (Jobe 2001) physiological definition (Walsh 2004) </ul> Pneumothorax (on chest X-ray) Duration of mechanical ventilation (intermittent positive pressure ventilation; days) Duration of respiratory support ( intermittent positive pressure ventilation or continuous positive airway pressure; days) Duration of oxygen therapy (days) Duration of hospital stay (days) Retinopathy of prematurity (any; requiring laser therapy) Necrotizing enterocolitis (any grade; requiring surgery) Need for blood transfusions Need for medical or surgical treatment for persistent ductus arteriosus Pulmonary hemorrhage Clinically apparent bleeding during treatment during the first week of life Central catheter (umbilical line or peripherally inserted central catheter) occlusion Stroke during treatment (yes/no) Cerebellar hemorrhage at brain ultrasound in the first month of life Cystic periventricular leukomalacia at brain ultrasound in the first month of life Brain magnetic resonance imaging (MRI) abnormalities at term equivalent age Cerebral hemodynamics impairment, based on cerebral near-infrared spectroscopy in the first three days of life Major neurodevelopmental disability assessed at ≥12 months of age (defined as cerebral palsy, developmental delay (Bayley or Griffith assessment more than two standard deviations (SD) below the mean) or intellectual impairment (intelligence quotient (IQ) more than two SD below mean), blindness (vision < 6/60 in both eyes) or sensorineural deafness requiring amplification </ul>
- Study Method
- Keyword
- Antithrombin III; Antithrombins; Cerebral Hemorrhage; Humans; Infant, Newborn; Infant, Premature
- Contact
- Organisational Affiliation
- Funding Source
- Other Selection Criteria
- Final Publication
- Same Topic Review
- Published Protocol
- Review Type
- Language
- English
- Country
- Review Stage
- First Submission Date
- Registration Date
- Anticipated Start Date
- Anticipated Completion Date
- Title Cn
- 抗凝血酶预防极早产儿脑室内出血 [Cochrane协议]
- Title En
- Antithrombin for the prevention of intraventricular hemorrhage in very preterm infants [Cochrane Protocol]
- Bilingual Status
- complete